Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT05212597

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05212597
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05212597. Randomized; no masking; primary purpose treatment. Start 2022-01-12 (actual); primary completion 2023-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB
Acronym
REVERSE-AR
Condition
Aortic Valve Insufficiency
Intervention (Drug)
Sacubitril-valsartan
Intervention (Drug)
Amlodipine-losartan
Lead sponsor
Samsung Medical Center (class: other)

Record details

Record id
cardio:ct-nct05212597
Content hash
569099b818ead6cbaf51218194d1b41736310a7a9e752ff670cca9e81f713f78